Chemotherapy Induced Neutropenia Pipeline Review, H1 2019 Edition – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Chemotherapy
Induced Neutropenia – Pipeline Review, H1 2019” drug pipelines
has been added to ResearchAndMarkets.com’s offering.

Chemotherapy
Induced Neutropenia – Pipeline Review, H1 2019, provides comprehensive
information on the therapeutics under development for Chemotherapy
Induced Neutropenia (Toxicology), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The
Chemotherapy Induced Neutropenia (Toxicology) pipeline guide also
reviews of key players involved in therapeutic development for
Chemotherapy Induced Neutropenia and features dormant and discontinued
projects. The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in
Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase
I and Preclinical stages are 5, 1, 5, 8, 6 and 8 respectively.
Similarly, the Universities portfolio in Preclinical stages comprises 1
molecules, respectively.

Chemotherapy Induced Neutropenia
(Toxicology) pipeline guide helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Chemotherapy Induced Neutropenia (Toxicology).
• The pipeline guide reviews pipeline therapeutics for Chemotherapy
  Induced Neutropenia (Toxicology) by companies and
  universities/research institutes based on information derived from
  company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Chemotherapy
  Induced Neutropenia (Toxicology) therapeutics and enlists all their
  major and minor projects.
• The pipeline guide evaluates Chemotherapy Induced Neutropenia
  (Toxicology) therapeutics based on mechanism of action (MoA), drug
  target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Chemotherapy Induced Neutropenia (Toxicology)

Companies Mentioned

• BeyondSpring Inc
• Biocon Ltd
• Bolder Biotechnology Inc
• Cellerant Therapeutics Inc
• Chong Kun Dang Pharmaceutical Corp
• Dr. Reddy’s Laboratories Ltd
• Enzychem Lifesciences Corp
• Gene Techno Science Co Ltd
• Generon (Shanghai) Corp Ltd
• GlycoMimetics Inc
• Hanmi Pharmaceuticals Co Ltd
• Lupin Ltd
• Mycenax Biotech Inc
• Nohla Therapeutics Inc
• Pangen Biotech Inc.
• Pfizer Inc
• Profarma
• Prolong Pharmaceuticals LLC
• Richter Gedeon Nyrt
• Sandoz International GmbH
• Tanvex BioPharma Inc
• USV Pvt Ltd
• Valenta Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/3wxh75/chemotherapy?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs